<DOC>
	<DOC>NCT00043316</DOC>
	<brief_summary>The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks. The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.</brief_summary>
	<brief_title>Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Key inclusion criteria: At least 12 years of age Diagnosis of cystic fibrosis with mild to moderate pulmonary impairment Must be receiving ongoing chronic treatment with TOBI (inhaled tobramycin) OR not receiving ongoing chronic treatment with TOBI and no use of TOBI or other inhaled antibiotic within 4 weeks prior to study drug administrationÂ· Other specific diagnostic indicators of CF and other factors must meet minimum requirements.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>pulmonary impairment</keyword>
</DOC>